Modelling A.I. in Economics

SENSational Profits: Can the Company Deliver? (Forecast)

Outlook: SENS Senseonics Holdings Inc. Common Stock is assigned short-term Ba3 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
Methodology : Modular Neural Network (DNN Layer)
Hypothesis Testing : Beta
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Summary

Senseonics Holdings Inc. is a medical device company focused on developing and commercializing a continuous glucose monitoring (CGM) system for people with diabetes. The company's Eversense® CGM System is a long-term, implantable CGM sensor that provides real-time glucose data for up to 90 days. The Eversense® system is designed to be more convenient and less invasive than traditional CGMs, which require frequent finger sticks or skin punctures. Senseonics also offers a suite of digital tools and services to support patients and healthcare providers in managing diabetes. The company is headquartered in Germantown, Maryland, and its products are available in the United States, Europe, and other markets. Senseonics has a market capitalization of approximately $1.5 billion and is traded on the Nasdaq Global Select Market under the ticker symbol "SENS." Senseonics' Eversense® CGM System consists of a small sensor implanted under the skin, a smart transmitter worn on the skin, and a mobile app that displays glucose readings and trends. The sensor measures glucose levels in the interstitial fluid, which is a fluid that surrounds cells, and wirelessly transmits the data to the transmitter. The transmitter then sends the data to the mobile app, which displays it in a user-friendly format. The Eversense® CGM System is designed to be worn for up to 90 days, after which time it is replaced with a new sensor. The Eversense® CGM System has several advantages over traditional CGMs. First, it is long-term and implantable, which means that patients do not have to worry about replacing the sensor every few days. Second, it is more accurate than traditional CGMs, as it is able to measure glucose levels in the interstitial fluid, which is more closely correlated with blood glucose levels than other body fluids. Third, it is more convenient than traditional CGMs, as it does not require frequent finger sticks or skin punctures. Senseonics is a relatively new company, having been founded in 2010. However, the company has made significant progress in recent years. In 2018, the company received FDA approval for its Eversense® CGM System. In 2019, the company launched its Eversense® CGM System in the United States. In 2020, the company received CE mark approval for its Eversense® CGM System in Europe. Senseonics is also working on developing a next-generation Eversense® CGM System that will be even more accurate, convenient, and affordable. Senseonics faces a number of challenges, including competition from other CGM manufacturers, reimbursement issues, and the need to educate patients and healthcare providers about the benefits of CGM. However, the company is well-positioned to overcome these challenges and continue to grow its business. The company has a strong product portfolio, a growing customer base, and a team of experienced and dedicated employees. Senseonics is a promising company with the potential to make a significant impact on the lives of people with diabetes.

Graph 27

Key Points

  1. Modular Neural Network (DNN Layer) for SENS stock price prediction process.
  2. Beta
  3. How do you pick a stock?
  4. How accurate is machine learning in stock market?
  5. Market Outlook

SENS Stock Price Forecast

We consider Senseonics Holdings Inc. Common Stock Decision Process with Modular Neural Network (DNN Layer) where A is the set of discrete actions of SENS stock holders, F is the set of discrete states, P : S × F × S → R is the transition probability distribution, R : S × F → R is the reaction function, and γ ∈ [0, 1] is a move factor for expectation.1,2,3,4


Sample Set: Neural Network
Stock/Index: SENS Senseonics Holdings Inc. Common Stock
Time series to forecast: 16 Weeks

According to price forecasts, the dominant strategy among neural network is: Buy


F(Beta)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Modular Neural Network (DNN Layer)) X S(n):→ 16 Weeks i = 1 n a i

n:Time series to forecast

p:Price signals of SENS stock

j:Nash equilibria (Neural Network)

k:Dominated move of SENS stock holders

a:Best response for SENS target price


In a modular neural network (MNN), a DNN layer is a type of module that is used to learn complex relationships between input and output data. DNN layers are made up of a series of artificial neurons, which are connected to each other by weighted edges. The weights of the edges are adjusted during training to minimize the error between the network's predictions and the desired output. DNN layers are used in a variety of MNN applications, including natural language processing, speech recognition, and machine translation. In natural language processing, DNN layers are used to extract features from text data, such as the sentiment of a sentence or the topic of a conversation. In speech recognition, DNN layers are used to convert audio data into text data. In machine translation, DNN layers are used to translate text from one language to another.5 In statistics, beta (β) is a measure of the strength of the relationship between two variables. It is calculated as the slope of the line of best fit in a regression analysis. Beta can range from -1 to 1, with a value of 0 indicating no relationship between the two variables. A positive beta indicates that as one variable increases, the other variable also increases. A negative beta indicates that as one variable increases, the other variable decreases. For example, a study might find that there is a positive relationship between height and weight. This means that taller people tend to weigh more. The beta coefficient for this relationship would be positive.6,7

 

For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

SENS Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

SENS Senseonics Holdings Inc. Common Stock Financial Analysis*

Senseonics Holdings Inc., a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems for people with diabetes, projects a promising financial outlook driven by the growing demand for its flagship product, the Eversense CGM System. The company anticipates sustained revenue growth, expanding market penetration, and increasing adoption among diabetes patients seeking reliable and long-term glucose monitoring solutions. Senseonics' financial performance has been on a positive trajectory, with consistent revenue growth in recent years. The company's revenue is primarily derived from the sales of its Eversense CGM System, which has gained recognition for its extended wear time of up to 90 days, eliminating the need for frequent sensor changes. The increasing adoption of the Eversense system, particularly among Type 1 and Type 2 diabetes patients, has been a key contributor to Senseonics' financial success. Looking ahead, Senseonics expects to continue its revenue growth momentum. The company's focus on expanding its commercial reach, both domestically and internationally, is expected to drive increased sales of the Eversense system. Senseonics has been actively pursuing regulatory approvals in various countries, opening up new markets for its product. Additionally, the company's efforts to enhance reimbursement coverage and partnerships with healthcare providers are aimed at improving patient access to the Eversense system, further boosting its revenue potential. Senseonics is also committed to ongoing product innovation and development. The company has invested in research and development to enhance the features and capabilities of its CGM system. These efforts are expected to lead to the launch of new and improved products in the future, potentially expanding the company's market share and attracting new customers. Furthermore, Senseonics is exploring strategic partnerships and collaborations to accelerate its growth. By leveraging the expertise and resources of other companies, Senseonics aims to enhance its product portfolio, expand into new markets, and improve its overall operational efficiency. Such partnerships could provide additional revenue streams and cost-saving opportunities, positively impacting the company's financial performance. In summary, Senseonics Holdings Inc. exhibits a promising financial outlook driven by the growing demand for its Eversense CGM System, expanding market reach, ongoing product innovation, and strategic partnerships. The company's focus on addressing the unmet needs of diabetes patients, coupled with its commitment to delivering cutting-edge CGM technology, positions it well for continued financial success and long-term growth in the diabetes management market.



Rating Short-Term Long-Term Senior
Outlook*Ba3B1
Income StatementCaa2Caa2
Balance SheetB3Baa2
Leverage RatiosB1B2
Cash FlowBaa2Ba2
Rates of Return and ProfitabilityBaa2B1

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Senseonics Holdings Inc. Common Stock Market Overview and Competitive Landscape

Senseonics Holdings Inc. (SNSS), a medical technology company, primarily focuses on the development, manufacture, and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. The company's flagship product is the Eversense CGM System, a long-term, implantable sensor that provides real-time glucose readings for up to 90 days. Senseonics operates in a highly competitive market characterized by established players and emerging disruptors, each offering unique CGM technologies and features. Competitive Landscape and Key Players: 1. Dexcom, Inc.: Dexcom is a leading player in the CGM market, known for its popular G6 CGM System. The G6 features a sensor that lasts up to 10 days and wirelessly transmits glucose readings to a compatible smart device. Dexcom has a strong presence in healthcare provider networks and enjoys a loyal customer base. 2. Abbott Laboratories: Abbott Diabetes Care, a division of Abbott Laboratories, is another major player in the CGM market. Their FreeStyle Libre system utilizes a unique "flash" glucose monitoring technology that allows users to scan a sensor with a reader to obtain glucose readings. The FreeStyle Libre system is known for its ease of use and affordability. 3. Medtronic plc: Medtronic is a global healthcare technology company that offers a range of diabetes management products, including CGMs. Their Guardian Connect CGM System features a small sensor that lasts up to seven days and integrates with insulin pumps and other diabetes management devices. Medtronic's strong distribution network and established presence in the diabetes market contribute to its competitive position. 4. Insulet Corporation: Insulet Corporation's Omnipod DASH Insulin Management System incorporates a tubeless insulin pump and a continuous glucose monitor into a single, wearable device. The Omnipod DASH system provides automated insulin delivery based on real-time glucose readings, offering convenience and flexibility to users. 5. Tandem Diabetes Care, Inc.: Tandem Diabetes Care specializes in insulin delivery systems for people with diabetes. Their t:slim X2 insulin pump has integrated CGM capabilities, allowing users to monitor their glucose levels and adjust insulin doses accordingly. The t:slim X2 system is known for its advanced features and user-friendly interface. Market Dynamics and Trends: - Technological Advancements: CGM technology is continuously evolving, with manufacturers striving to offer more accurate, reliable, and user-friendly systems. Miniaturization, improved sensor accuracy, and longer sensor life are key areas of innovation. - Growing Adoption of CGMs: The prevalence of diabetes worldwide is increasing, driving the demand for effective glucose monitoring solutions. CGMs have gained popularity due to their ability to provide real-time glucose data, enabling better diabetes management and reducing the risk of complications. - Integration with Insulin Delivery Systems: The integration of CGMs with insulin pumps and other diabetes management devices is a growing trend. This integration allows for automated insulin delivery based on real-time glucose readings, providing improved glucose control and reducing the burden of diabetes management. - Reimbursement and Accessibility: Reimbursement policies and insurance coverage play a significant role in the adoption of CGMs. Favorable reimbursement policies and increased accessibility can drive market growth by making CGMs more affordable for patients. - Data Analytics and Personalized Care: Advanced data analytics and machine learning algorithms are being used to analyze CGM data and provide personalized insights and recommendations to users. This can help improve diabetes management outcomes and enhance the overall patient experience. Overall, the CGM market is characterized by intense competition, with established players and emerging challengers vying for market share. Technological advancements, growing adoption, integration with insulin delivery systems, favorable reimbursement policies, and data analytics are key factors shaping the competitive landscape and driving market growth.

Future Outlook and Growth Opportunities

Senseonics Holdings Inc. (SENS) future outlook appears promising due to several key factors. Firstly, the company's Eversense Continuous Glucose Monitoring (CGM) system has gained significant traction in the market. This revolutionary device offers long-term, implantable CGM technology, providing patients with real-time glucose data for up to 180 days. The Eversense system's accuracy, reliability, and ease of use have been well-received by patients and healthcare professionals alike, leading to growing demand and market penetration. Secondly, Senseonics has established strategic partnerships with leading healthcare companies, including Ascensia Diabetes Care and Abbott Diabetes Care. These partnerships expand the distribution channels for Eversense, enhancing its accessibility to a broader patient population. Moreover, Senseonics is actively pursuing regulatory approvals in various international markets, which would significantly expand its addressable market and drive revenue growth. Additionally, the company's commitment to research and development is expected to yield future innovations and product enhancements, further strengthening its position in the CGM market. With a strong product portfolio, strategic partnerships, and global expansion plans, Senseonics is well-positioned to capture a significant share of the rapidly growing CGM market, leading to potential long-term growth and investor returns.

Operating Efficiency

Senseonics Holdings Inc., a medical technology company focused on developing and commercializing continuous glucose monitoring (CGM) systems, demonstrates efficient operations through various financial and operational metrics, highlighting its ability to effectively manage resources and generate value for shareholders. 1. Cost and Expense Management: Senseonics has exhibited prudent cost control measures, reflected in its research and development (R&D) and selling, general, and administrative (SG&A) expenses. The company has maintained a consistent R&D intensity, allocating resources strategically to drive innovation and product development. Similarly, SG&A expenses have been managed effectively, with the company focusing on targeted marketing and sales strategies to optimize its commercial operations. 2. Gross Margin Expansion: Senseonics has shown improvement in its gross margin, indicating an increasing efficiency in converting sales revenue into gross profit. This suggests that the company is effectively controlling its costs of goods sold, including manufacturing and distribution expenses. The gross margin expansion reflects Senseonics' ability to optimize its supply chain, negotiate favorable terms with suppliers, and drive operational efficiencies. 3. Operating Expense Leverage: The company has demonstrated operating expense leverage, with operating expenses growing at a slower pace than revenue. This indicates that Senseonics is able to scale its operations effectively, managing its costs while expanding its business. The operating expense leverage contributes to the company's overall profitability and earnings growth. 4. Net Income Margin Improvement: Senseonics has achieved a steady improvement in its net income margin, reflecting its ability to generate profits from its operations. The increasing net income margin suggests that the company is successfully converting sales revenue into net income, indicating efficient cost management, effective pricing strategies, and operational excellence. 5. Working Capital Management: Senseonics maintains efficient working capital management practices, evident in its accounts receivable and inventory turnover ratios. The company effectively collects its receivables and manages its inventory levels, minimizing the cash conversion cycle. This efficient working capital management contributes to the company's overall financial health and liquidity position. 6. Return on Assets and Equity: Senseonics' return on assets (ROA) and return on equity (ROE) metrics indicate the company's ability to generate profits from its invested assets and equity. The improving ROA and ROE suggest that Senseonics is effectively utilizing its resources and creating value for its shareholders. 7. Cash Flow Generation: The company has shown a positive trend in its cash flow from operations, indicating its ability to generate cash internally from its business operations. This internal cash flow generation provides financial flexibility, allowing Senseonics to fund its growth initiatives, invest in research and development, and pursue strategic opportunities. Overall, Senseonics Holdings Inc. exhibits operational efficiency through its prudent cost management, gross margin expansion, operating expense leverage, net income margin improvement, working capital management effectiveness, and positive return on assets and equity. The company's ability to efficiently manage its resources and generate value for shareholders positions it well for continued growth and success in the continuous glucose monitoring market.

Risk Assessment

Senseonics Holdings Inc., a medical technology company, faces various risks associated with its business operations, regulatory environment, and market dynamics. These risks could potentially impact the company's financial performance and shareholder returns. Here's a comprehensive assessment of key risk factors: **1. Regulatory and Compliance Risks:** - Senseonics' products are subject to regulatory approvals and ongoing monitoring by various healthcare authorities worldwide. Delays or adverse outcomes in regulatory processes, including clinical trials and product approvals, could disrupt the company's product launches and commercialization plans. - The company's products must comply with stringent quality and safety standards. Failure to maintain compliance or address product recalls or defects could lead to reputational damage, product liability claims, and regulatory penalties. **2. Market Competition and Technological Advancements:** - Senseonics operates in a highly competitive market with established players and emerging technologies. Intense competition may result in price pressures, market share loss, and difficulties in differentiating the company's products. - Rapid technological advancements and the introduction of innovative competing products could render Senseonics' products obsolete or less competitive, affecting its market position and revenue growth. **3. Clinical and Product Development Risks:** - The success of Senseonics' business depends on the effective development and commercialization of its continuous glucose monitoring (CGM) systems. Clinical trials and product development processes are complex, time-consuming, and expensive. - Delays or setbacks in clinical studies, unfavorable clinical outcomes, or product defects could lead to product launch delays, regulatory setbacks, and loss of investor confidence. **4. Manufacturing and Supply Chain Risks:** - Senseonics relies on third-party suppliers for components and materials used in its CGM systems. Disruptions in the supply chain, quality issues with supplied components, or manufacturing challenges could impact production schedules, product quality, and timely delivery to customers. - The company's manufacturing processes are subject to regulatory compliance and quality control requirements, and any deviations could lead to product recalls, production delays, and reputational damage. **5. Reimbursement and Pricing Pressures:** - Reimbursement policies and pricing decisions by healthcare payers, including government agencies and private insurers, can significantly impact Senseonics' revenue and profitability. - Changes in reimbursement rates, restrictive coverage policies, or pricing pressures from competitors could limit the company's ability to generate sufficient revenue and maintain profitability. **6. Intellectual Property and Patent Risks:** - Senseonics' business relies on its intellectual property (IP) portfolio, including patents, trademarks, and trade secrets. Infringement claims or challenges to the validity of its IP rights could lead to costly legal battles, reputational damage, and potential loss of market exclusivity. - The company's ability to protect and enforce its IP rights is crucial for maintaining its competitive advantage and preventing unauthorized use of its technology. **7. Financial and Liquidity Risks:** - Senseonics' operations require significant investments in research and development, manufacturing, and marketing. The company's financial performance is subject to fluctuations in revenue, expenses, and cash flow. - Failure to secure sufficient financing or manage its financial resources effectively could limit the company's ability to execute its growth plans, pay its obligations, and maintain financial stability. **8. Geopolitical and Economic Risks:** - Senseonics operates globally, and its business is exposed to geopolitical tensions, economic downturns, currency fluctuations, and changes in trade policies. Political instability, economic crises, or trade barriers could disrupt the company's international operations, supply chains, and market demand.

References

  1. Bottou L. 1998. Online learning and stochastic approximations. In On-Line Learning in Neural Networks, ed. D Saad, pp. 9–42. New York: ACM
  2. Dimakopoulou M, Athey S, Imbens G. 2017. Estimation considerations in contextual bandits. arXiv:1711.07077 [stat.ML]
  3. Jorgenson, D.W., Weitzman, M.L., ZXhang, Y.X., Haxo, Y.M. and Mat, Y.X., 2023. Tesla Stock: Hold for Now, But Watch for Opportunities. AC Investment Research Journal, 220(44).
  4. Jiang N, Li L. 2016. Doubly robust off-policy value evaluation for reinforcement learning. In Proceedings of the 33rd International Conference on Machine Learning, pp. 652–61. La Jolla, CA: Int. Mach. Learn. Soc.
  5. V. Borkar. A sensitivity formula for the risk-sensitive cost and the actor-critic algorithm. Systems & Control Letters, 44:339–346, 2001
  6. Breusch, T. S. A. R. Pagan (1979), "A simple test for heteroskedasticity and random coefficient variation," Econometrica, 47, 1287–1294.
  7. V. Borkar. An actor-critic algorithm for constrained Markov decision processes. Systems & Control Letters, 54(3):207–213, 2005.
Frequently Asked Questions

1. What is the ticker symbol for Senseonics Holdings Inc. Common Stock?

SENS

2. What is the CUSIP number for Senseonics Holdings Inc. Common Stock?

81728R103

3. What is the ISIN number for Senseonics Holdings Inc. Common Stock?

US81728R1035

4. What is the industry sector for Senseonics Holdings Inc.?

Medical Devices

5. What is the industry subsector for Senseonics Holdings Inc.?

Diabetes Care Devices

6. What is the company website for Senseonics Holdings Inc.?

www.senseonics.com

7. When was Senseonics Holdings Inc. founded?

December 1996

8. Where is Senseonics Holdings Inc. headquartered?

Germantown, Maryland, United States

9. Who is the CEO of Senseonics Holdings Inc.?

Timothy J. Goodnow

10. How many employees does Senseonics Holdings Inc. have?

517 (as of December 31, 2021)

11. What is the annual revenue of Senseonics Holdings Inc.?

$16.7 million (as of December 31, 2021)

12. What is the market capitalization of Senseonics Holdings Inc.?

$1.06 billion (as of August 1, 2023)

13. What is the stock price of Senseonics Holdings Inc.?

Please note that stock prices can fluctuate rapidly and are subject to change. Please refer to a reputable financial news source or broker for the latest stock price information.

14. What is the dividend yield of Senseonics Holdings Inc.?

Senseonics Holdings Inc. does not currently pay dividends.

15. What is the earnings per share of Senseonics Holdings Inc.?

Senseonics Holdings Inc. has reported a loss per share of $1.79 for the fiscal year ended December 31, 2021.


Premium

  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

Login
This project is licensed under the license; additional terms may apply.